Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
celiac disease
Biotech
Equillium swaps subcutaneous cytokine inhibitor for oral option
Equillium is dropping one IL15/21-targeting Celiac drug over underwhelming data and replacing it in the pipeline with another multi-cytokine inhibitor
James Waldron
Dec 21, 2023 10:58am
Takeda taps Innate to develop celiac antibody-drug conjugates
Apr 3, 2023 5:08am
GSK drops celiac disease program acquired in Sitari buyout
Feb 1, 2023 6:40am
9 Meters' celiac drug doesn't measure up in phase 3
Jun 21, 2022 2:13pm
Forte's top shareholder calls on the company to liquidate
May 25, 2022 11:29am
Equillium adds 3 drugs to pipeline via $329M Bioniz buy
Feb 16, 2022 7:00am